NASDAQ:SMMT Summit Therapeutics Q3 2026 Earnings Date & Estimates $15.80 +1.00 (+6.76%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$16.12 +0.32 (+2.03%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Summit Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 7:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeAfter Market ClosesConference Call7:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Summit Therapeutics in Q3 2026Summit Therapeutics is expected to post earnings of -$0.2817 per share on revenue of $111 thousand. In the same quarter a year earlier Summit Therapeutics reported -$0.31 per share. Summit Therapeutics last reported on July 23, 2026, posting -$0.28 per share and missing the -$0.2744 consensus estimate. Summit Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2817Expected Revenue$111 thousandPrior-Year EPS-$0.31Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.28 (Missed by -$0.0056)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Summit Therapeutics Q3 2026 Earnings FAQ When does Summit Therapeutics report Q3 2026 earnings? Summit Therapeutics (NASDAQ:SMMT) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Summit Therapeutics' Q3 2026 earnings call? Summit Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Summit Therapeutics? Analysts expect Summit Therapeutics to post earnings of -$0.2817 per share for Q3 2026. How much revenue is Summit Therapeutics expected to report? The consensus revenue estimate for Summit Therapeutics is $111 thousand for Q3 2026. Summit Therapeutics Earnings HeadlinesSummit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI DealOctober 30, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Stock Breaks Above Two Hundred Day Moving Average - Time to Sell?October 30, 2026 | americanbankingnews.comDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 SOctober 25, 2026 | gurufocus.comIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaOctober 25, 2026 | businesswire.comLunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentOctober 23, 2026 | prnewswire.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases. Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings. Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company. Akeso retains rights in China, while Summit is responsible for development and commercialization activities across its licensed international territories. The company has roots in the United Kingdom and was historically involved in developing treatments for infectious diseases before shifting its strategic focus to oncology. Summit is led by Robert W. Duggan, who serves as chairman and chief executive officer, and conducts its clinical development and business activities through operations serving global markets.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
